TRAX

41.6406.34%
RI

Rita I. Jain

Independent Non-Employee Director

Dr. Rita I. Jain, M.D. is Independent Director of SAB Biotherapeutics, Inc. from January 7, 2026. She is an Independent Director of Avalo Therapeutics, Inc. from June 17, 2025. She serves as a Independent Non-Employee Director at First Tracks Biotherapeutics, Inc. She was Independent Director at AnaptysBio, Inc. since April 03, 2023 until April 20, 2026. She is Independent Director at Celldex Therapeutics, Inc. from February 2023. She serves as Independent Director at Provention Bio, Inc. since January 2023 until April 27, 2023. She had been Executive Vice President and Chief Medical Officer of ChemoCentryx, Inc. since October 05, 2021 until October 20, 2022 and served as its Executive Employee Director until October 20, 2022. From August 2021 to December 2023, Dr. Jain served as Chief Executive Officer of Heartwood Biopharma Group. Dr. Jain oversees development activities including clinical development, development operations, regulatory affairs and drug safety and pharmacovigilance. She served as Member of Supervisory Board at AM-Pharma B. V. since July 2020 until September 2023. Dr. Jain served as Chief Medical Officer at Immunovant, Inc since January 2021 until May 2021. Dr. Jain served as Independent Director of ChemoCentryx, Inc. since March 27, 2019 until 2022. Dr. Jain, a board-certified rheumatologist, serves as a Member of the Supervisory Board of AM Pharma. She served as Chief Medical Officer and Senior Vice President at Akebia Therapeutics, Inc. since May 2017 until June 17, 2019. She has led all aspects of clinical development across a diverse set of therapeutic areas including immunology, inflammation and nephrology, among others. Dr. Jain was responsible for leading the clinical development of Akebia’s HIF pipeline, including the global Phase 3 development program for vadadustat, an oral HIF stabilizer in development for the treatment of anemia related to chronic kidney disease. From 2013 to 2016, She was the Vice President of Men’s and Women’s Health and Metabolic Development at AbbVie, Inc. and where she led the successful completion of the Phase II uterine fibroid program and the Phase III endometriosis program, which led to the FDA approval for ORILISSA (elagolix), managing endometriosis pain. She also led development programs in a number of areas including, cystic fibrosis, men’s health, respiratory and pain development. In her time at AbbVie and Abbott, she oversaw the development of more than 15 new chemical entities and marketed products. She held several senior leadership roles at Abbott Laboratories from 2003 through 2012, including Vice President in Pharmaceutical Development and various management positions at Pharmacia Corp. Dr. Jain also led activities in pain, respiratory, cystic fibrosis development, arthritis, inflammation and pain Group at G. D. Searle, which was acquired by Pharmacia and later, Pfizer. Dr. Jain led the design and execution of multiple late stage programs for high impact products, including Orlissa® and Oriahnn®. She has also held faculty position at the North Shore University Hospital where she was the Director of the Program in Novel Therapeutics. She served as an as Assistant Professor of Medicine at New York University School of Medicine. Dr. Jain earned her M. D. at the State University of New York at Stony Brook School of Medicine and her B. S. in Biology from Long Island University/C. W. Post. She completed her medical training in internal medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.

Positions